| abstract |
The present disclosure relates to compounds of Formula (I):, and the pharmaceutically acceptable salts and solvates thereof, wherein A, m, X, Y, Z, and B 1 are as defined as set forth in the specification. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing a condition or disorder responsive to the degradation of CBP/P300 proteins (e.g., cancer). |